Choosing the Number of Doses and the Cohort Size for Phase 1 Dose-Escalation Studies

This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different dose schedules and cohort sizes. The methodology described is motivated by the situation of phase 1 dose-escalation studies in oncology, that is, a single dose administered to each patient, with a single binary response (“toxicity” or “no toxicity”) observed. It is likely that a wider range of applications of the methodology is possible. In this paper, results from 10000-fold simulation runs conducted using the software package Bayesian ADEPT are presented. Four designs were compared under six scenarios. The simulation results indicate that there are slight advantages of having more dose levels and smaller cohort sizes.

[1]  J O'Quigley,et al.  Dose‐Finding Designs for HIV Studies , 2001, Biometrics.

[2]  John Whitehead,et al.  Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. , 2006, Statistics in medicine.

[3]  J Whitehead,et al.  Bayesian decision procedures based on logistic regression models for dose-finding studies. , 1998, Journal of biopharmaceutical statistics.

[4]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[5]  J Whitehead,et al.  Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. , 2001, Biostatistics.

[6]  J Whitehead,et al.  Bayesian decision procedures for dose determining experiments. , 1995, Statistics in medicine.

[7]  D. Kerr,et al.  Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  S. Møller,et al.  An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.

[9]  S Zohar,et al.  The continual reassessment method: comparison of Bayesian stopping rules for dose‐ranging studies , 2001, Statistics in medicine.

[10]  J Whitehead,et al.  A novel Bayesian decision procedure for early-phase dose-finding studies. , 1999, Journal of biopharmaceutical statistics.

[11]  Ethan Reiner,et al.  A stopping rule for the continual reassessment method , 1998 .

[12]  Yinghui Zhou,et al.  Practical Implementation of Bayesian Dose-Escalation Procedures , 2003 .

[13]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[14]  I. Todd,et al.  The Design of Clinical Trials in Cancer Therapy , 1972, British Journal of Cancer.

[15]  Thomas M Braun,et al.  The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. , 2002, Controlled clinical trials.